Hedera Dx raises €15M Series A
Scaling on-site precision oncology infrastructure and real-world data.
In oncology, timing is everything. Yet for millions of patients, access to molecular diagnostics and the targeted therapies they unlock remains slow, centralized, and unevenly distributed. Hedera Dx is changing that.
This week, Hedera Dx announced a €15M Series A round to scale its decentralized, hospital-run liquid biopsy testing model. The round was led by Vsquared Ventures, with participation from existing investors.
Rather than operating its own commercial lab, Hedera Dx enables hospitals to perform advanced blood-based cancer diagnostics in-house. The company provides a comprehensive 32-gene circulating tumor DNA (ctDNA) panel, standardized lab protocols compatible with existing next-generation sequencing (NGS) instruments, and a cloud-based software layer for variant calling and clinical interpretation.
Enabling diagnostics at the edge
Most genomic cancer testing today is centralized. Patients have their blood drawn or tissue biopsy taken in one hospital, the sample is shipped to a reference lab in another city or country, and results arrive a week or more later. This model has worked reasonably well in the U.S. with large national payors, commercial lab scale, and a handful of dominant precision oncology players. But it doesn’t translate well to Europe or to much of the rest of the world.
Hedera’s premise is simple: cancer diagnostics should be locally available, fast, and scalable. By equipping hospital labs to run liquid biopsies themselves, the company cuts turnaround time from 10–14 days down to under 48 hours. That time matters. It enables more responsive treatment decisions, faster adjustments when therapies fail, and better integration with the pace of clinical care.
The platform is already deployed in hospital labs across 11 countries, including Switzerland, Germany, France, Italy, Spain, and the Netherlands. These are public hospitals and regional cancer centers, not elite private institutions, which speaks to the practicality of Hedera’s model. This isn't about labs becoming genomics research centers. It's about giving them tools they can use without rebuilding workflows or retraining entire teams.
Liquid biopsy as infrastructure for cancer care
Liquid biopsy is often discussed in terms of blockbuster tests: early detection screens, minimal residual disease assays, tumor profiling panels. But the companies that win long-term will be those that build durable diagnostic infrastructure—flexible enough to support new tests, easy to integrate, and hard to displace once embedded.
Hedera is aiming to become that layer. Its system is test-agnostic and already expanding beyond tumor profiling. With this funding round, the company will accelerate development of new assays for minimally residual disease and early detection, while expanding its analytics capabilities via Hedera Frame, a real-world data platform aggregating clinical and molecular insights across its customer base.
Why this model fits Europe
European hospitals are under pressure to modernize cancer care, but centralized models often conflict with national health systems, procurement structures, and data privacy regulation. Hedera’s model is well-suited to this context: it keeps data local, respects institutional autonomy, and integrates with standard lab equipment already in use.
This decentralization also has second-order benefits. It allows hospitals to maintain ownership of their clinical data, avoid vendor lock-in, and participate in shared real-world evidence networks without sacrificing control. Hedera’s software layer turns each participating lab into both a testing site and a data node, accelerating the feedback loop between practice and evidence.
From a commercial perspective, the company benefits from network effects: the more hospitals using its platform, the stronger its dataset and analytics tools become. And because it's embedded in workflows and IT systems, switching costs are high.
Real-world data generation
Hedera Dx is actively collaborating with leading cancer centers and patient organizations to generate clinicogenomic evidence through its Hedera Frame platform. This global, prospective, patient-centric data hub gathers clinical information, tumor genomics data, and resulting outcomes from patients with solid tumors who have undergone NGS-based molecular testing. By ensuring reference quality for computational methods, Hedera Frame aids the advancement of agile, real-world evidence-based clinical trials, contributing to the development of next-generation tumor biomarkers and groundbreaking therapies.
One notable initiative is the EMPATHY NSCLC study, the first prospective clinical validation and real-world utility study for the European, NGS-based decentralized liquid biopsy approach. This multicenter study enables real-world assessment of current ctDNA-based liquid biopsy practices in hospital laboratories across a dozen leading European cancer centers. It also represents the first asset of a larger, pan-cancer longitudinal clinicogenomics evidence effort aiming to collect real-life testing patterns with liquid biopsies, ultimately unleashing the potential of this highly promising technology and developing the next generation of breakthrough personalized therapies.
By harnessing the power of its clinicogenomics evidence and tapping into deep clinical expertise, the company generates unique prospective outcomes that drive advancements in precision medicine. Collaborative efforts encompass a range of offerings, including state-of-the-art software analysis and ctDNA assays, with full adherence to IVDR compliance.
To enhance patient engagement, Hedera Dx has developed the myHedera app. This application enables patients to actively participate in their care by providing Patient-Reported Outcomes and Patient-Reported Experience Measures, placing patients at the center of their own care and fostering a collaborative relationship between healthcare providers, patient groups, and individuals.
Scaling with a €15M Series A
This Series A is about scaling commercial rollout across Europe, additional regulatory approvals, and broader clinical utility. Hedera will invest in its core product suite, expand the Hedera Frame data platform, and begin developing a pipeline of future assays designed for decentralized deployment.
There’s also an enterprise element to the next phase: deeper integration into hospital informatics, more robust compliance infrastructure, and tighter feedback between lab users and the central team to fine-tune protocols and analytics.
The broader shift
What Hedera Dx is doing reflects a broader shift in oncology: from centralized, episodic testing to distributed, continuous monitoring. Cancer care is increasingly managed over time, like a chronic disease. That shift demands diagnostics that are faster, more frequent, and more embedded in the fabric of routine care.
For that to work, hospitals need infrastructure, not just access to a lab down the road, but the ability to generate, interpret, and act on molecular data themselves. Hedera’s bet is that every modern hospital will eventually run some version of this capability in-house. Its job is to make that transition as seamless and valuable as possible.
The next decade of oncology won’t just be about better drugs. It will be about retooling the systems that deliver and care to patients.